'Nanovaccine' reverses type 1 diabetes in mice

April 8, 2010

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

Type 1 diabetes (T1D) is a chronic autoimmune disease that results from destruction of insulin-producing by certain white blood cells, called T cells. "Unfortunately, eliminating the rather extensive repertoire of harmful T cells that attack the pancreas cannot currently be done without also eliminating T cells that protect us from infections and cancer," explains Dr. Pere Santamaria, from the Julia McFarlane Diabetes Research Centre at the University of Calgary in Alberta.

Dr. Santamaria and colleagues wanted to find a way to counteract the harmful autoimmune response without compromising general immunity. They discovered that our bodies have a built-in mechanism that tries to stop the progression of autoimmune diseases like T1D. "Essentially, there is an internal tug-of-war between aggressive T- cells that want to cause the disease and weaker T cells that want to stop it from occurring," says Dr. Santamaria.

The researchers also developed a unique and inventive nanotechnology-based "vaccine" that selectively boosted the weak white blood T cells, enabling them to effectively counter the damage caused by their overactive T cell relatives. The vaccine consisted of nanoparticles (NPs, spheres thousands of times smaller than a single cell of the body) "coated" with individual T1D-relevant protein fragments bound to self MHC molecules (pMHC). MHC molecules are used by another type of white blood cell, called an "antigen presenting cell" to "present" antigen to as part of all immune responses.

Using a of T1D, the researchers discovered that their nanovaccine blunted T1D progression in prediabetic mice and restored normal blood sugar in diabetic mice. Further, NPs displaying human diabetes-relevant complexes restored normal blood sugar levels in a humanized model of diabetes. The authors pointed out that only the disease-generated responded to the pMHC-NP therapy, so the treatment would be inconsequential in healthy individuals because it would not have nonspecific effects on the immune system.

"If the paradigm on which this nanovaccine is based holds true in other chronic , such as multiple sclerosis, rheumatoid arthritis, and others, pMHC-nanovaccines might find general applicability in autoimmunity," suggests Dr. Santamaria. "In principle, the pMHC nanovaccines could be engineered with any disease-relevant pMHC complex as long as it is involved in the diseases process."

Explore further: Immune responses spread from one protein to another in type 1 diabetes

More information: Tsai et al.: “Reversal of Autoimmunity by Boosting Memory-like Autoregulatory T Cells.” Publishing in Immunity 32, Vol, 4, April 23, 2010. www.immunity.com/

Related Stories

Type 1 diabetes triggered by 'lazy' regulatory T-cells

January 14, 2008

A research team led by Dr. Ciriaco A. Piccirillo of McGill University’s Department of Microbiology and Immunology has discovered that in some individuals, the specialized immunoregulatory T-cells that regulate the body’s ...

Recommended for you

New nanomaterial maintains conductivity in 3-D

September 4, 2015

An international team of scientists has developed what may be the first one-step process for making seamless carbon-based nanomaterials that possess superior thermal, electrical and mechanical properties in three dimensions.

Graphene made superconductive by doping with lithium atoms

September 2, 2015

(Phys.org)—A team of researchers from Germany and Canada has found a way to make graphene superconductive—by doping it with lithium atoms. In their paper they have uploaded to the preprint server arXiv, the team describes ...

Making nanowires from protein and DNA

September 3, 2015

The ability to custom design biological materials such as protein and DNA opens up technological possibilities that were unimaginable just a few decades ago. For example, synthetic structures made of DNA could one day be ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.